Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 5;14(19):4877.
doi: 10.3390/cancers14194877.

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer

Zeyuan Zheng  1 , Jinxin Li  1 , Yankuo Liu  1 , Zhiyuan Shi  1 , Zuodong Xuan  1 , Kunao Yang  1 , Chunlan Xu  1 , Yang Bai  1 , Meiling Fu  1 , Qiaohong Xiao  2 , Huimin Sun  3 , Chen Shao  1
Affiliations
Review

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer

Zeyuan Zheng et al. Cancers (Basel). .

Abstract

Prostate cancer (PCa) has the second highest incidence of malignancies occurring in men worldwide. The first-line therapy of PCa is androgen deprivation therapy (ADT). Nonetheless, most patients progress to castration-resistant prostate cancer (CRPC) after being treated by ADT. As a second-generation androgen receptor (AR) antagonist, enzalutamide (ENZ) is the current mainstay of new endocrine therapies for CRPC in clinical use. However, almost all patients develop resistance during AR antagonist therapy due to various mechanisms. At present, ENZ resistance (ENZR) has become challenging in the clinical treatment of CRPC. AR splice variant 7 (AR-V7) refers to a ligand-independent and constitutively active variant of the AR and is considered a key driver of ENZR in CRPC. In this review, we summarize the mechanisms and biological behaviors of AR-V7 in ENZR of CRPC to contribute novel insights for CRPC therapy.

Keywords: AR-V7; LncRNA; castration-resistant prostate cancer; drug resistance; enzalutamide; proteostasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The Structure of AR-FL and AR-Vs. The human AR gene contains eight exons; AR has four domains, including NTD, DBD, HD and LBD. Exon 1 encodes NTD, DBD is encoded by exons 2 and 3, exon 4 encodes HD, and LBD is encoded by exons 5,6,78; AR-V7 has no LBD, so enzalutamide cannot bind to AR-V7; The DBD domain of AR-V3 is only encoded by exon 2, and lacks zinc finger; AR45 starts coding from exon 1b and lacks the NTD domain; The DBD domain formed by AR8 is only encoded by exon 3 and is not functional. AR8 inserts 69 nucleotides upstream of exon 3; AR-V567es does not contain exon 5.6.7; UTR: Untranslated Region; AR-FL: full-length androgen receptor; AR-V: androgen receptor splicing variant; NTD: N-end domain; DBD: DNA binding; HD: hinge domain; LBD: ligand binding domain; CE3: recessive exon 3; AF: Activate the function.
Figure 2
Figure 2
Enzalutamide acts on the AR signaling pathway. Enzalutamide binds to the LBD and blockades the AR signaling pathway by blocking the binding of androgens to AR, impeding the AR nuclear translocation, and inhibiting the AR transcriptional activity. AR-FL: full-length androgen receptor; AR-V7: androgen receptor splice variant 7; DHT: dihydrotestosterone. HSP: heat shock proteins.
Figure 3
Figure 3
Natural/compound drugs affect the transcriptional activity and protein stability of AR-V7 through the HSP family. ARVib, JG98, and C86 promote AR-V7 degradation by inhibiting HSP40/HSP70 axis; bruceantin promotes AR-V7 degradation by directly binding to HSP90 and disrupting the interaction between HSP90 and AR-V7; KRIBB3 promotes the degradation of AR by interacting with HSP27; niclosamide not only inhibits the transcriptional activity of AR-V7 but also promotes the degradation of AR-V7.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur. Urol. 2017;71:630–642. doi: 10.1016/j.eururo.2016.08.002. - DOI - PubMed
    1. Scott L.J. Enzalutamide: A review in castration-resistant prostate cancer. Drugs. 2018;78:1913–1924. doi: 10.1007/s40265-018-1029-9. - DOI - PubMed
    1. Davies A., Conteduca V., Zoubeidi A., Beltran H. Biological evolution of castration-resistant prostate cancer. Eur. Urol. Focus. 2019;5:147–154. doi: 10.1016/j.euf.2019.01.016. - DOI - PubMed